Experience

Davis Polk advised the underwriters in connection with Alector, Inc.’s $240 million public offering of 9,602,500 shares of common stock, which includes the 1,252,500 shares offered pursuant…

Davis Polk advised the joint book-running managers in connection with an initial public offering of 10,586,316 shares of common stock of Black Diamond Therapeutics, Inc. In addition,…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $207 million public offering of common stock of Denali Therapeutics,…

Davis Polk advised Zai Lab Limited in connection with its follow-on offering of approximately $300 million of American depositary shares, representing 5,500,000 ordinary shares by the…

Davis Polk advised the underwriters in connection with the SEC-registered offering of 3,152,712 shares of common stock of Applied Therapeutics, Inc., including 411,223 shares of common…

Davis Polk advised the underwriters on the SEC-registered initial public offering by I-Mab of 7,407,400 American depositary shares, each 10 ADSs representing 23 ordinary shares, for total…

Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Notre Dame Intermédica and Bain Capital, a shareholder of Notre Dame Intermédica, of…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $195.6 million public offering of common stock of Forty Seven, …

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $224.3 million offering of common stock of Constellation…

Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule…